Actavis, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products, has launched a generic version of Boehringer Ingelheim's Catapres-TTS (Clonidine Transdermal System, USP, 0.1 mg/day, 0.2 mg/day, and 0.3 mg/day for one week), following the receipt of final approval on its Abbreviated New Drug Application from the US Food and Drug Administration.

Catapres-TTS is a transdermal therapeutic system indicated for the treatment of hypertension.  For the 12 months ending February 28, 2014, Catapres-TTS had total US sales of approximately $180 million, according to IMS Health data.